Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. AN Co. Ltd.
WARNING LETTER
•AN Co. Ltd.•May 30, 2017

AN Co. Ltd. – FDA Warning Letter, May 30, 2017

Record Details

The FDA inspected AN Co. Ltd.'s drug manufacturing facility in Korea from May 29-30, 2017, identifying significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals (21 CFR parts 210 and 211). Consequently, the firm's drug products are deemed adulterated under section 501(a)(2)(B) of the FD&C Act. Key violations include the failure to thoroughly investigate out-of-specification (OOS) results (21 CFR 211.192), as demonstrated by an uninvestigated OOS viscosity result. The firm also failed to follow an adequate written stability testing program (21 CFR 211.166(a)), specifically by not testing products in their actual packaging and lacking assay for active ingredient in stability protocols. Furthermore, AN Co. Ltd. failed to establish and follow adequate control procedures for process validation (21 CFR 211.110(a)), with no process performance qualification studies or ongoing monitoring. The FDA found the firm's responses deficient and requested detailed OOS procedures, stability protocol revisions, process validation timelines and protocols, and a risk assessment for unvalidated products. The letter strongly recommends engaging a CGMP consultant. Failure to correct these violations could result in the FDA withholding new application approvals and refusing admission of products into the U.S. The firm must respond within 15 working days outlining corrective actions and a completion schedule.

Company
AN Co. Ltd.
Inspection date
May 30, 2017
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · eed690c0-8844-4f33-83ba-91e57475343d

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.19221 CFR 211.166(a)21 CFR 211.110(a)21 CFR 211.34FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)

Full citation text and observation details available on the Dashboard.

Other documents for AN Co. Ltd.
  • 483 - 2017-05-30May 30, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore AN Co. Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.